Clinical trial
Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell…
NCT00059813 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00059813 |
|---|---|
| Title | Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer |
| Official title | A Phase II Trial of G3139 (Genasense) Anti-Bcl-2 Antisense Oligonucleotide Plus Alpha-Interferon in Metastatic Renal Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer |
| Intervention type | Biological, Other |
| Interventions | recombinant interferon alfa, oblimersen sodium, pharmacological study |
| Enrollment | 41 |
| Start date | Aug 1, 2003 |
| Primary completion | Jun 1, 2005 |
| First posted | May 7, 2003 |
| Last update posted | Aug 26, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: